Allogeneic haematopoietic stem cell transplant (allo-HSCT) offers potentially curative therapy for patients with relapsed/refractory lymphoid malignancies. Reduced-intensity conditioning (RIC) with Alemtuzumab reduces transplant-related mortality and graft-versus-host disease (GvHD), but may be associated with increased risk of relapse. With the aim of studying the effect of GVHD and donor lymphocyte infusions (DLI) on relapse, we performed a retrospective study of 288 patients (57% non-Hodgkin lymphoma, 24% Hodgkin lymphoma and 19% chronic lymphocytic leukaemia; 58% were relapsed/refractory) who underwent RIC-Alemtuzumab-HSCT between 2000 and 2012. Median follow-up time for survivors was 64 months. Five-year overall survival, relapse incidence, GvHD/relapse-free survival and non-relapse mortality were 47%, 33%, 37% and 28% respectively. Cumulative incidence of grade II-IV acute and extensive chronic GvHD was 22% and 21% at 100 days and 5 years respectively. On multivariate analysis, presence of GvHD (P = 0Á03) and unrelated donor type (P = 0Á03) were protective of relapse. 62/288 patients received DLI for either mixed donor chimerism (prophylactic DLI, n = 37) or clinical relapse (therapeutic DLI, n = 25). Prophylactic and therapeutic DLI successfully converted the patient to full or stable mixed donor chimerism in 78% and 56% of patients respectively. These data demonstrate good longterm outcomes and support the concept of the graft-vs-lymphoma effect as a key protective factor against relapse following RIC-Alemtuzumab allo-HSCT for patients with mature lymphoid malignancies.
GvHD, facilitating broader use of allo-HSCT in older, more co-morbid patients (Genadieva-Stavrik et al, 2016) . However, RIC with Alemtuzumab theoretically risks abrogating GvLymph activity due to T-cell depletion (Butcher & Collins, 2005) .
The indications, outcomes and use of RIC-Alemtuzumabconditioned allo-HSCT in patients with mature lymphoid malignancies are largely unknown and reported in small, heterogeneous cohorts (Faulkner et al, 2004; Morris et al, 2004; Peggs et al, 2007; Rabitsch et al, 2016) . Furthermore, the outcomes of prophylactic DLI (p-DLI) in patients at risk of relapse, and therapeutic DLI (t-DLI) in patients following relapse have been reported in small patient cohorts only (Thomson et al, 2008 (Thomson et al, , 2010 Peggs et al, 2011) .
The aims of this study were (i) to describe long term outcomes of a homogeneously RIC-Alemtuzumab-conditioned cohort of patients undergoing allo-HSCT for mature lymphoid malignancy; (ii) to analyse evidence for the graft-versus-lymphoma effect in this setting; (iii) to describe the use and outcomes following prophylactic and therapeutic DLI in this cohort.
Methods

Patient cohort
Consecutive patients aged >18 years undergoing first Alemtuzumab-based RIC allo-HSCT for mature lymphoid malignancy between 2000 and 2012 at three UK tertiary haematology transplant centres (Birmingham, Glasgow and Oxford) were included. All patients gave written consent before transplant for the collection and analysis of anonymous data in subsequent studies of transplant outcomes. All patients received Alemtuzumab as part of the conditioning regimen.
Use of donor lymphocyte infusion
Donor lymphocyte infusions were given at the clinician's discretion. Mixed chimerism was confirmed on at least 2 separate tests before p-DLI and clinical relapse was confirmed on disease re-staging prior to t-DLI. Where patient and donor factors permitted, DLI were given 3-monthly, generally according to the following escalating schedule: 1 9 10 6 CD3+ cells/kg; 3 or 5 9 10 6 CD3+ cells/kg; 1 9 10 7 CD3+ cells/kg; 3 or 5 9 10 7 CD3+ cells/kg; 1 9 10 8 CD3+ cells/kg.
Dosing was the same for recipients of volunteer unrelated donors (VUDs) and sibling donors.
Statistical analysis
Relapse incidence (RI), overall survival (OS), GvHD/relapsefree survival (GRFS), non-relapse mortality (NRM), incidence of acute and chronic graft-versus-host disease (aGvHD/ cGvHD) and use and outcomes of DLI were analysed.
GRFS was defined as absence of relapse, grade 3/4 aGvHD and extensive cGvHD at 5 years. Kaplan-Meier estimates were used to determine the unadjusted probability of OS and GRFS to 5 years post-transplant. Differences between the curves were determined by the log-rank test. Cox regression was used to examine the independent effect of clinical factors on outcomes. Cumulative incidence in a competing risk setting using the method of Fine and Gray was used to calculate the following (competing risk for each event denoted in brackets): RI (death in remission), TRM (relapse), grades 2-4 aGvHD (death before day 100 without grades 2-4 aGvHD) and extensive cGvHD (death without extensive cGvHD). A P < 0Á05 was considered significant. All tests were two-sided. Scaled Schoenfield residuals were used to test against nonproportionality.
Variables considered in univariate and multivariate analyses were recipient age at time of transplantation, primary diagnosis [non-Hodgkin lymphoma (NHL) versus Hodgkin lymphoma (HL) versus chronic lymphocytic leukaemia (CLL)], number of previous lines of therapy (≤2 vs. ≥3), previous autograft, patient sex, donor characteristics [type (VUD versus matched sibling donor), sex, human leucocyte antigen (HLA) match (8/8 or 10/10 vs. any other), ABO match], transplant characteristics [centre, date pre/post median (2000-2008 or 2008-2012 , a natural data defined cut-off point), disease status (complete remission (CR) versus not CR), conditioning regimen fludarabine/melphalan/alemtuzumab (FMC) versus other, alemtuzumab dose > median versus < median, stem cell source (peripheral blood versus bone marrow), stem cell dose, cytomegalovirus (CMV) recipient/donor status. For continuous variables, the median was the cut-off point.
For multivariate analysis, OS and GRFS were analysed by multivariate Cox proportional hazard models and RI, NRM, cGvHD and aGvHD by cause-specific hazards. A backward stepwise model selection approach was used to identify significant risk factors, and independent variables with P > 0Á1 were excluded sequentially from the models. 95% confidence intervals (CIs) were calculated and arms compared by the Wald test. An interaction term was used to accommodate the interaction between HLA match and donor type. As only one time-dependent co-variate can be included in a multivariate Cox model, two multivariate Cox models were constructed to allow evaluation of the impact of GvHD and DLI respectively on relapse.
Statistical analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-pro ject.org), and SPSS (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 24. Armonk, NY: IBM Corp).
Results
Patient and donor characteristics
A total of 288 consecutive adult patients undergoing first Alemtuzumab-based RIC allo-HSCT for mature lymphoid malignancy between 2000 and 2012 were included for analysis (Table I) . 164 (57%) had a diagnosis of NHL, 68 (24%) had HL and 56 (19%) had CLL. Detail on histological subtype is available in Table I . The median age at HSCT was 47 years (range 17-68) and 60% were male.
A total of 158 patients (55%) received stem cells from an HLA-matched unrelated donor, and 130 (45%) from a HLAmatched sibling. 270 (94%) received a peripheral blood stem cell transplant and 18 (6%) bone marrow stem cells. Patients were heavily pre-treated prior to allo-HSCT, with 128 (44%) having received ≥3 prior lines of treatment. Approximately half of patients (49%) had received a previous auto-HSCT. 118 (41%) of patients were in CR at time of allo-HSCT. The most frequent conditioning regimen was FMC (201 patients, 70%), with the next most common regimen being carmustine, etoposide, cytarabine and melphalan (BEAM) (74 patients, 36%). The median total Alemtuzumab dose was 50 mg (range 30-100). Median duration of follow-up for survivors was 64 months.
Overall transplant outcomes
The RI, NRM, OS, GvHD and GRFS were analysed for the overall cohort. At 5 years, RI, NRM, OS and GRFS were 33Á1%, 27Á6%, 47Á4% and 37Á2% respectively (Fig 1) .
Factors predictive of outcomes following allo-HSCT for mature lymphoid malignancy
Relapse. On univariate analysis (Table II) , factors predictive of relapse at 5 years were age less than median (37Á5% vs. 28Á2%, P = 0Á044), HLA full match (35Á7% vs. 9Á7%, P = 0Á010) and sibling donor type (42Á1% vs. 25Á6%, P = 0Á001) (See Fig 2 for cumulative incidence curves). Factors protective against relapse were GvHD pre-DLI [hazard ratio (HR) 0Á486, P = 0Á014]. Alemtuzumab dose greater than the median showed a trend towards increased relapse (37Á5% vs. 27Á2%, P = 0Á06). Recipients of DLI were at increased risk of relapse (HR 1Á9, P = 0Á05), which is accounted for by those receiving t-DLI, who were highly likely to progress to a further relapse (HR 4Á6, P = 0Á001), while recipients of p-DLI did not (HR 1Á2, P = 0Á652).
On multivariate analysis (Tables III), only GvHD pre-DLI remained protective against relapse (HR 0Á5, P = 0Á03). To accommodate the interaction between HLA match and sibling donor type, an interaction term was created, which remained significant in the multivariate model (P = 0Á03). Fully HLA matched sibling donors led to an increased risk of relapse compared to matched unrelated donor (HR 0Á58, P = 0Á015) and HLA-mismatched unrelated donors (HR 0Á276, P = 0Á03). Taken together, these data suggest that patients with less than full HLA matching, unrelated donors and those who developed GvHD were protected against relapse. Overall survival. Factors adversely associated with 5-year OS were previous autograft (38Á1% vs. 57Á4%, P = 0Á003), disease status [CR vs. partial remission (PR) vs. active disease (AD), 55Á2% vs. 47Á3% vs. 19Á4, P = 0Á001], and number of previous treatments ≥3 (42Á3% vs. 58Á3%, P = 0Á007). In time-dependent analyses, t-DLI was associated with increased risk of death (HR 2Á4, P = 0Á003), whereas p-DLI was not (HR 1Á07, P = 0Á829). On multivariate analysis, disease status (P = 0Á03: PR HR 1Á3, P = 0Á23, AD HR 2Á67 P = 0Á001), previous autograft (HR 1Á99, P = 0Á0003) and patient age > median retained significance (HR 1Á8, P = 0Á02). The most common causes of deaths were disease relapse and sepsis, with further detail given in Table SI. GRFS. Factors adversely associated with 5-year GRFS were disease status at allo-HSCT (CR vs. PR vs. AD, 45Á3% vs. 35Á7% vs. 10Á3, P = 0Á001), previous autograft (28Á3% vs. 44Á9%, P = 0Á004) and ≥3 previous lines of treatment (31Á6% vs. 47Á8%, P = 0Á008). CMV recipient/donor status had a significant impact on GRFS (neg/neg 44Á4%, neg/pos 21Á4%, pos/pos 27Á0%, pos/neg 41Á4%, P = 0Á013). On multivariate analysis, disease status (P = 0Á003: PR HR 1Á4, P = 0Á064, AD HR 2Á51 P = 0Á001), ≥3 lines of treatment (HR 1Á6, P = 0Á014) and CMV recipient/donor status (P = 0Á009: R/D neg/pos HR 2Á1, P = 0Á008, R/D pos/pos HR 1Á8, P = 0Á007) retained significance (see Fig 3) .
NRM. Factors predictive of 5-year NRM were previous autograft (33Á9% vs. 21Á5%, P = 0Á022), ≥3 previous lines of treatment (33Á9% vs. 14Á2%, P = 0Á001), HLA incomplete match (48Á4% vs. 25Á0%, P = 0Á004), FMC as conditioning regimen (31Á0% vs. 19Á6%, P = 0Á028), and patient age > median (35Á1% vs. 20Á6%, P = 0Á004). In time-dependent analyses, GvHD pre-DLI increased NRM with a HR 2Á3 (P = 0Á0001). This was caused by both grade II-IV aGvHD (HR 1Á8, P = 0Á015) and extensive cGvHD (HR 2Á6, P = 0Á0001). On multivariate analysis, GvHD pre-DLI (HR 2Á0, P = 0Á008) and patient age > median (HR 2Á3, P = 0Á001) retained significance. Heavily pre-treated, older patients and those developing GvHD were thus at significant increased risk of transplant-related death.
Graft-versus-host disease. The incidence of grade II-IV aGvHD at 100 days was 22Á1%. Predictors of aGvHD were FMC as conditioning regimen (26Á6% vs. 11Á6%, P = 0Á004) and donor type VUD (28Á8% vs. 13Á9%, P = 0Á004). On multivariate analysis, none retained significance. In a landmark analysis from 100 days, 5-year cumulative incidence of extensive cGvHD was 20Á8%. Factors associated with increased cGvHD were patient age > median (28Á8% vs. 13Á9%, P = 0Á004), Alemtuzumab dose < median (29Á7% vs. 14Á7%, P = 0Á003), date of transplant pre-median (27.% vs. 15Á3%, P = 0Á02), transplant centre (Birmingham 14Á6% vs. Glasgow 25Á6% vs. Oxford 26Á1%, P = 0Á04) and CMV donor/recipient status (neg/neg 13Á5%, neg/pos 36Á4%, pos/ pos 31Á0%, pos/neg 14Á6%, P = 0Á005). On multivariate analysis, only date of transplant post-median retained significance (HR 0Á36, P = 0Á002).
DLI following allo-HSCT for mature lymphoid malignancy. Indications and outcomes of DLI in patients following allo-HSCT were evaluated (Table IV) . 62/288 (21Á5%) patients received DLI: 37 receiving p-DLI for mixed chimerism and 25 receiving t-DLI for disease relapse. 36/62 (58Á1%) were from sibling donors, 26/62 (41Á9%) from unrelated donors. In most cases, immunosuppression was tapered or discontinued to induce a GvLymph effect. 7/25 received additional chemotherapy prior to t-DLI. The median dose of DLI received was 1 9 10 6 CD3+ cells/kg (range 0Á1-1 9 10 7 ). Median time from HSCT to first DLI was 10Á5 months (range 3-30), to 2nd DLI 15 months (6-51) and to 3rd DLI 19 months (9-30). There was no difference in time to DLI based on donor type, indicating that there was no difficulty in obtaining DLI from unrelated donors. 29/37 (78%) of p-DLI and 14/25 (56%) of t-DLI recipients achieved full or stable mixed chimerism. Following DLI, 5-year OS was 59Á3%. As expected, this was significantly lower in patients receiving t-DLI compared to p-DLI (34Á2% t-DLI vs. 75Á9% p-DLI, P = 0Á04). 5-year RI post-DLI was 43Á3% (27Á2% for p-DLI, 70Á3% for t-DLI, P = 0Á04, see Fig 4 for survival curves) . 5-year NRM post-DLI was 10Á1% (11Á1% for p-DLI, 8Á9% for t-DLI, P = 0Á71).
The cumulative incidence of GvHD at 5 years post-DLI was 32Á3% (p-DLI 21Á6%, t-DLI 48%, P = 0Á04). 2 patients (3Á2%) died of GvHD post-DLI. Median time to GvHD after last DLI was 46 days (range 17-249). In time-dependent analyses, there was no protective effect of GvHD post-DLI At risk (n) Overall survival, GRFS, relapse incidence, non-relapse mortality. GRFS, graft-versus-host-disease/relapse free survival; HSCT, haematopoietic stem cell transplantation; NRM, non -relapse mortality; OS, overall survival; RI, relapse incidence. 
Discussion
This large series examined the long-term outcomes after Alemtuzumab-based RIC allo-HSCT for mature lymphoid malignancy. RIC comprises around 75% of current conditioning regimens and is set to increase as allo-HSCT is performed in older and more co-morbid patients (Bhatt, 2016) . Harnessing the GvLymph effect to modify risk of relapse and concomitant treatment failure is critical to improving RIC allo-HSCT outcomes.
There have been ongoing concerns that alemtuzumab may lead to increased risk of relapse by reducing GvHD and abrogating the GvLymph effect (Delgado et al, 2011) . In this multicentre cohort, using GvHD as a proxy for GvLymph, a GvLymph effect could be demonstrated as both GvHD and unrelated donor transplant were protective of relapse. Importantly, GvHD also increased non-relapse mortality on multivariate analysis (HR 2Á0, P = 0Á008) and so any strategies potentiating GvHD must be approached with caution. There was also a possible alemtuzumab dose effect, as dose> median (>50 mg) significantly reduced the incidence of cGvHD (14Á7 vs. 29Á7%, P = 0Á003), and a trend to increased relapse rates (P = 0Á06). This corroborates a recent study that identified that the risk of GvHD was significantly higher in a 50 mg cohort when compared to recipients of 100 mg or 60 mg alemtuzumab (15% vs. 2-6%) (Green et al, 2017) . Recipients of sibling allo-HSCT were at increased risk of relapse in our study, which raises important questions about alemtuzumab use in sibling donors in mature lymphoid malignancy. Therefore, based on our results, alemtuzumab 
No variables retained significance on multivariate analysis Chronic GvHD Date Pre-median (11Á02Á2008) 1Á00 0Á0015 Post-median 0Á36 AD, active disease; CMV, cytomegalovirus; CR, complete remission; D, donor; DLI, donor lymphocyte infusion; GRFS, graft-versus-host-disease/relapse free survival; GvHD, graft-versushost-disease; NRM, non-relapse mortality; OS, overall survival; PR, partial remission; R, recipient; RI, relapse incidence; VUD, volunteer unrelated donor. Values given as n (%) or median (range). CLL, chronic lymphocytic leukaemia; DLI, donor lymphocyte infusion; GvHD, graft-versus-host-disease; HL, Hodgkin lymphoma; HSCT, haematopoietic stem cell transplantation; MDC, mixed donor chimerism; NHL, non-Hodgkin lymphoma; OS, overall survival; p-DLI, prophylactic donor lymphocyte infusion; RI, relapse incidence; t-DLI, therapeutic donor lymphocyte infusion. Time/months 36·00 30·00 24·00 18·00 12·00 6·00 ·00
Graft-and relapse-free survival should probably be avoided in the HLA-matched sibling setting because it decreases the GVLymph effect. In our cohort, using p-DLI to potentiate the GvLymph effect in patients was a highly effective strategy and our findings indicate the importance of serial monitoring to predict early relapse after allo-HSCT. 78% of patients were effectively converted to full or stable mixed donor chimerism, and only 27% went on to relapse at 5 years. In the poor prognostic cohort of patients with clinical relapse who received t-DLI, 56% achieved a period of full/stable mixed donor chimerism although 70% ultimately progressed. Nonetheless, 30% of previously relapsed patients were alive and in remission at 5 years after receiving t-DLI. Incidence of GvHD was comparable to that expected post allo-HSCT and may be related to concomitant tapering of immunosuppression rather than DLI itself. However, contrary to other reports, there was an increased risk of NRM in those experiencing GvHD post-DLI (Liga et al, 2013; Scarisbrick et al, 2015) . Our study was underpowered to formally evaluate GvHD characteristics of patients who developed GvHD de novo versus post-DLI, but this should be evaluated in the setting of a prospective study.
The composite endpoint, GRFS, denotes ideal recovery from HSCT, describing a patient who is disease-free without ongoing morbidity: 5-year GRFS was 37Á2% in our cohort. Interestingly, CMV recipient/donor status had a significant impact on GRFS, which was maintained on multivariate analysis. CMV can reactivate or cause primary infection in CMV sero-positive recipients, or if a sero-negative recipient receives a graft from a sero-positive donor. The mortality of CMV disease remains high despite potent antiviral agents, such as ganciclovir, and CMV seropositivity is a known independent risk factor for developing aGvHD (Broers et al, 2000) . In our study, recipient/donor status neg/pos or pos/ pos was associated with a high GRFS failure rate (21% and 27% vs. 44% and 41% for neg/neg and pos/neg). The important impact of CMV serology of the donor in this setting may be related to impaired immune reconstitution secondary to the use of alemtuzumab (van der Heiden et al, 2018) . Donors with positive CMV serology should be avoided where possible, independent of the patient's CMV serology.
There was no difference in 5-year outcome by primary diagnosis (HL versus NHL versus CLL). By contrast, disease status at allo-HSCT had a significant impact on OS and GRFS, which was maintained on multivariate analysis, with patients with active disease at allo-HSCT experiencing very poor long-term disease outcomes (5-year OS 19Á4%, 5-year GRFS 10Á3%). This reflects the high-risk disease in this cohort, and the need for novel strategies for these patients.
Our study has intrinsic limitations inherent to any retrospective analysis. We were unable to evaluate the impact of CMV reactivation on outcome due to unavailable data, and had to rely on CMV recipient/donor serostatus as a proxy. Patients in the cohort included patients treated over a course of 12 years, with possible changes to supportive care, GvHD prophylaxis and transplant regimens. The date of transplant was taken forward as a variable on multivariate analysis to account for survivorship bias. DLI was performed based on individual physician decisions, with consequent range in schedule and dosing of DLI. Our study also included patients with a range of underlying primary diagnoses (HL, NHL, CLL), although there was no significant impact of disease subtype on outcome. Significant questions remain unanswered regarding optimal use of DLI in this context. A well-controlled, randomised trial of allograft and DLI for mature lymphoid malignancy to establish standardized DLI therapy protocols is warranted. Such a study would set out to recruit patients who develop falling donor chimerism or have high risk disease features post allo-HSCT for mature lymphoid malignancy, who are off immunosuppressive therapy without clinical signs of GvHD, uncontrolled infection or a recent history of >grade 2 acute GvHD. Patients would be randomized to a DLI versus no-DLI strategy. Doses of DLI would be standardised to e.g. 5 9 10 6 , 1 9 10 7 , 5 9 10 7 CD3+ cells/kg for related donors, and 1 9 10 6 , 5 9 10 6 , 1 9 10 7 CD3+ cells/kg for unrelated donor. The key outcome should be disease response, donor chimerism and observed toxicity to DLI. Such a study is unlikely to occur for the foreseeable future and, for now, large observational cohorts such as this provide an evidence base for practice in challenging patient cohorts.
Conclusions
The major findings from this study were that allo-HSCT provides the prospect of long-term remission and survival for this difficult, multiply-relapsed patient cohort. The GvLymph effect is likely to be a key determinant of long-term outcome.
p-DLI is highly effective at converting patients back to full donor chimerism and enables long-term remission, while t-DLI can re-induce remission in some patients. The clinical benefit of DLI, scheduling, dosing and combination with novel therapies awaits formal assessment in a comparative prospective trial.
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